ubiquinol
UBIQUINOL is a reduced form of coenzyme Q10, a lipid-soluble molecule that consists of an aromatic ring and a 10-unit isoprenoid chain. It is naturally produced by the body. A significant increase in plasma CoQ10 status observed after supplementation in one study suggested that UBIQUINOL is a better supplemental form to enhance the CoQ10 status than ubiquinone (the oxidized form of Q10). UBIQUINOL has also been found to reduce oxidative stress induced by strenuous exercise. Oxidative stress is associated with aging and many chronic diseases, such as cardiovascular diseases, cancers, and cognitive decline. Ubiquinol has furthermore been shown to improve mitochondrial oxidative metabolism in the brain, and cognitive improvement was found as a result of Ubiquinol intake in chronic fatigue syndrome patients. UBIQUINOL is considered safe, but can have side effects such as upper abdominal pain, loss of appetite, nausea, diarrhea and headaches. CoQ10 might make blood-thinning drugs, such as warfarin (Coumadin, Jantoven), less effective. This could increase the risk of a blood clot. — NCATS
Clinical trial activity
19 trials · 21 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2005 (NCT00891917)
Timeline
Indications
Studied for
- Diabetes Mellitus · Phase 2/Phase 3
- Down Syndrome · Phase 2
- Drugs, Investigational · Phase 3
- Fatigue Syndrome, Chronic · Phase 3
- Fertilization in Vitro · Phase 2
- Gulf War · Phase 3
- Health · Phase 4
- Heart Arrest · Phase 2
- Heart Failure · Phase 2
- Huntington Disease · Phase 1
- Infertility, Male · Phase 2
- Inflammation · Phase 2/Phase 3
- Oxidative Stress · Phase 2/Phase 3
- Parkinson Disease · Phase 2
- Polycystic Ovary Syndrome · Phase 2/Phase 3
- Reproductive Health · Phase 2
- Sepsis · Phase 2
- Sprains and Strains · Phase 2/Phase 3
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
SMILES
COC1=C(OC)C(O)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(C)=C1O- Mol. weight
- 865.3594 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaUbiquinol ↗
- NCATSM9NL0C577Y ↗
Also known as
- ubiquinol
- ubiquinol
- ubiquinol
- ubiquinol
- ubiquinol 0
- ubiquinol 1
- ubiquinol 50
- ubiquinol 6 (ubiquinol 30)
- ubiquinol 7
- ubiquinol 9
- ubiquinols
- ubiquinone hydroquinone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06640465 | Phase 4 | Oct 31, 2024 | Ovation Fertility |
| NCT06555575 | Phase 2 | Sep 1, 2024 | Trio Fertility |
| NCT05847257 | Phase 2 | Dec 1, 2021 | Al-Mustansiriyah University, Al-Nahrain University |
| NCT05178225 | N/A | May 1, 2021 | Abecma, Kaneka Corporation |
| NCT04286178 | N/A | Mar 1, 2020 | University of Toronto |
| NCT04870502 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2019 | Saudi German Hospital - Madinah |
| NCT04312152 | N/A | Mar 9, 2019 | Associazione Italiana Sindrome di Phelan-McDermid (AISPHEM), University of Bari, University of Messina |
| NCT03372109 | N/A | Nov 14, 2017 | LIfe Extension, Supplement Formulators, Inc. |
| NCT02865460 | Phase 3 | Feb 1, 2017 | Department of Veteran Affairs |
| NCT02847585 | N/A | Aug 1, 2016 | Chung Shan Medical University |
| NCT02779634 | Phase 2 | Jul 1, 2016 | Hebrew University |
| NCT02934555 | Phase 2 | Mar 1, 2016 | Harvard University, Kaneka Corporation |
| NCT02622672 | Phase 2/Phase 3 (Phase 3) | Jan 4, 2016 | Chung Shan Medical University |
| NCT01940627 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2013 | University of Granada |
| NCT01948063 | Phase 2 | Oct 1, 2012 | Harvard University, Kaneka Corporation |
| NCT01702987 | N/A | Oct 1, 2012 | Harvard University |
| NCT03061513 | Phase 2 | Feb 28, 2012 | Cornell University |
| NCT00980694 | Phase 1 | Sep 1, 2009 | Kaneka Corporation, University of Rochester |
| NCT00891917 | Phase 2 | Jan 1, 2005 | University of Cincinnati |
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kaneka Corporation | For profit | 4 | 0 | 3 | 2009 |
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2012 |
| Chung Shan Medical University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Abecma | For profit | 1 | 1 | 1 | 2021 |
| Al-Mustansiriyah University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Al-Nahrain University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Associazione Italiana Sindrome di Phelan-McDermid (AISPHEM) | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2017 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| LIfe Extension | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ovation Fertility | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Saudi German Hospital - Madinah | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Supplement Formulators, Inc. | For profit | 1 | 1 | 1 | 2017 |
| Trio Fertility | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Bari | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of Granada | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Messina | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2009 |